银屑病患者可溶性LOX-1与冠状动脉病变的关联
该队列研究纳入175例银屑病患者(其中138例随访1年),用ELISA法盲法检测血清可溶性LOX-1(sLOX-1),并用冠状动脉CT血管造影(CCTA)量化非钙化冠脉负荷(NCB)。结果显示银屑病患者sLOX-1高于年龄性别匹配对照,且与PASI评分及NCB独立相关;1年时PASI改善者的sLOX-1下降与NCB下降相关。
要点
- sLOX-1在银屑病患者中升高,且与PASI评分相关。
- sLOX-1与NCB的关联独立于高脂血症、传统心血管危险因素、他汀使用及生物制剂治疗。
- PASI改善>50%者1年内sLOX-1下降与NCB下降相关。
核心结论
- sLOX-1在银屑病患者中升高并与皮损严重程度相关。
- sLOX-1与NCB独立于高脂血症状态相关,提示炎症诱导的sLOX-1可能调节银屑病中富含脂质的NCB。
- 皮损改善与1年时sLOX-1下降相关,提示sLOX-1在银屑病炎症性动脉粥样硬化形成中的潜在作用。
研究设计与样本
- 研究为美国国立卫生研究院(NIH)的队列研究,2013年1月1日至2017年10月1日从门诊皮肤科转诊连续纳入175例银屑病患者。
- 138例连续招募的银屑病患者完成1年随访。
- sLOX-1由现场科学家用酶联免疫吸附试验(ELISA)盲法检测未稀释血清。
- CCTA由对患者人口学、访视及治疗状态设盲的读者量化3支主要心外膜冠状动脉的NCB。
主要发现
- 175例银屑病患者平均(SD)年龄49.7(12.6)岁,男性91例(55%)。
- Framingham风险评分中位数2.0(IQR 1.0-6.0),平均(SD)BMI 29.6(6.0)。
- 银屑病患者sLOX-1高于年龄性别匹配对照(中位数210.3 [IQR 110.9-336.2] vs 83.7 [IQR 40.1-151.0];P < .001)。
- sLOX-1与PASI评分相关(β = 0.23;95% CI 0.082-0.374;P = .003)。
- sLOX-1与NCB独立于高脂血症状态相关(β = 0.11;95% CI 0.016-0.200;P = .023),校正传统心血管危险因素、他汀使用及生物制剂治疗后仍持续(β = 0.10;95% CI 0.014-0.193;P = .03)。
关键数值与推荐
- sLOX-1与NCB关联的效应量β = 0.11(95% CI 0.016-0.200;P = .023),校正后β = 0.10(95% CI 0.014-0.193;P = .03)。
- sLOX-1与PASI评分关联β = 0.23(95% CI 0.082-0.374;P = .003)。
- 1年时sLOX-1下降与NCB下降关联β = 0.14(95% CI 0.028-0.246;P = .02)。
临床怎么用
- 对银屑病患者可关注sLOX-1作为炎症相关冠脉非钙化负荷的潜在生物标志物。
- 皮损严重度改善(如PASI改善>50%)可能伴随sLOX-1及NCB下降,支持系统性炎症控制对心血管风险的潜在益处。
- sLOX-1与NCB的关联独立于高脂血症及他汀使用,提示评估心血管风险时不应仅依赖传统血脂指标。
局限性
- 研究为单中心NIH队列,样本量175例、随访1年,结果外推需谨慎。
- 原文未报告对照组的具体来源与匹配细节。
- 原文未报告sLOX-1检测的批间变异或检测限等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Psoriasis, a chronic inflammatory skin disease associated with accelerated noncalcified coronary burden (NCB) by coronary computed tomography angiography (CCTA), accelerates lipoprotein oxidation in the form of oxidized modified lipoproteins. A transmembrane scavenger receptor for these oxidized modified lipoproteins is lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1), which has been reported to be associated with coronary artery disease. It is unknown whether this receptor is associated with coronary artery disease in psoriasis. OBJECTIVE: To assess the association between soluble LOX-1 (sLOX-1) and NCB in psoriasis over time. DESIGN, SETTING, AND PARTICIPANTS: In a cohort study at the National Institutes of Health, 175 consecutive patients with psoriasis were referred from outpatient dermatology practices between January 1, 2013, and October 1, 2017. A total of 138 consecutively recruited patients with psoriasis were followed up at 1 year. EXPOSURES: Circulating soluble lectinlike oxidized low-density lipoprotein receptor-1 levels were measured blindly by field scientists running undiluted serum using an enzyme-linked immunosorbent assay. MAIN OUTCOMES AND MEASURES: Coronary computed tomography angiography scans were performed to quantify NCB in all 3 major epicardial coronary arteries by a reader blinded to patient demographics, visit, and treatment status. RESULTS: Among the 175 patients with psoriasis, the mean (SD) age was 49.7 (12.6) years and 91 were men (55%). The cohort had relatively low median cardiovascular risk by Framingham risk score (median, 2.0 [interquartile range (IQR), 1.0-6.0]) and had a mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) suggestive of overweight profiles (29.6 [6.0]). Elevated sLOX-1 levels were found in patients with psoriasis compared with age- and sex-matched controls (median, 210.3 [IQR, 110.9-336.2] vs 83.7 [IQR, 40.1-151.0]; P < .001), and were associated with Psoriasis Area Severity Index (PASI) score (β = 0.23; 95% CI, 0.082-0.374; P = .003). Moreover, sLOX-1 was associated with NCB independent of hyperlipidemia status (β = 0.11; 95% CI, 0.016-0.200; P = .023), an association which persisted after adjusting for traditional cardiovascular risk factors, statin use, and biologic psoriasis treatment (β = 0.10; 95% CI, 0.014-0.193; P = .03). At 1 year, in those who had clinical improvement in PASI (eg, >50% improvement), a reduction in sLOX-1 (median, 311.1 [IQR, 160.0-648.8] vs median, 224.2 [IQR, 149.1 - 427.4]; P = .01) was associated with a reduction in NCB (β = 0.14; 95% CI, 0.028-0.246; P = .02). CONCLUSIONS AND RELEVANCE: Soluble lectinlike oxidized low-density lipoprotein receptor-1 levels were elevated in patients with psoriasis and were associated with severity of skin disease. Moreover, sLOX-1 associated with NCB independent of hyperlipidemia status, suggesting that inflammatory sLOX-1 induction may modulate lipid-rich NCB in psoriasis. Improvement of skin disease was associated with a reduction of sLOX-1 at 1 year, demonstrating the potential role of sLOX-1 in inflammatory atherogenesis in psoriasis.
引用
- Dey AK, Gaddipati R, Elnabawi YA, et al. Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis. JAMA Dermatol. 2020. PMID: 31746956. doi:10.1001/jamadermatol.2019.3595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。